IR/PR

Here are new updates from NovMetaPharma.
Notice
NovDB2, IND submitted for US FDA Phase 2c clinical trial

Registration date : 2020.11.20

NovMetaPharma Co., Ltd. submitted an Investigational New Drug (IND) to the US FDA for Phase 2c clinical trial of NovDB2 in December 31, 2019. The clinical trial protocol, the core of this clinical Phase 2c IND, was designed under the supervision of Professor. Johan Auwerx, our Head of Strategic Committee(HSC) and registered member of the Board of Directors.

Attach Files : none

  • < Prev Progress of US FDA Phase 2c clinical trial
  • Next > Application filed for a US patent for COVID-19 treatment
List